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The Epstein-Barr virus immediate-early protein BZLF1 mediates the switch from latent to lytic infection.
BZLF1 transcription can be derived from either the BZLF1 promoter or the BRLF1 promoter (Rp). Productive
viral infection of EBV-infected B cells can be induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ment, as well as cross-linking of surface immunoglobulin with antiimmunoglobulin antibody. Both TPA and
antiimmunoglobulin antibody are known to activate expression of the cellular transcription factor Zif268 in B
cells. In this study, we have examined the regulation of BZLF1 transcription by Zif268. We show that Rp (but
not the BZLF1 promoter) is activated by Zif268. Bacterially synthesized Zif268 binds strongly to an upstream
sequence in the Rp promoter (located from 2131 to 2123 relative to the start site) and more weakly to a
proximal sequence (249 to 240). Zif268 activation of Rp requires these two Zif268 binding sites. TPA
treatment of B cells induces the expression of Zif268 protein, which binds to Rp. Furthermore, TPA activation
of Rp requires the upstream Zif268 site. These findings indicate that Zif268 can activate a critical Epstein-Barr
virus immediate-early promoter and, therefore, may play a key role in the regulation of viral latency.
Epstein-Barr virus (EBV) is a human herpesvirus which can
infect and replicate in oral epithelial cells (31, 38). In contrast,
EBV infection of B cells is generally latent (31, 38). Reactiva-
tion of the lytic cycle in latently infected B cells can be achieved
by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA)
or cross-linking of surface immunoglobulin (51, 57). In addi-
tion, overexpression of the EBV immediate-early (IE) gene
product, BZLF1 (Z), is sufficient to disrupt latency (8, 11, 30,
43, 44, 52).
The Z gene product can be derived from two different pro-
moters (35). The more proximal promoter (Z promoter [Zp])
directs transcription of a 0.9-kb message which makes the Z
gene product alone (35) and a spliced variant of Z missing the
middle exon (32) (Fig. 1A). In addition, the Z gene product
can also be derived from a second promoter, BRLF1 (R)
promoter (Rp) (35). Rp directs transcription of two bicistronic
messages (3.8 and 2.9 kb), which code for both the Z and the
R IE proteins (35). The Z and R IE proteins have been shown
to function synergistically in activating the expression of early
EBV promoters (7, 8, 13, 28, 41). In addition, a 0.9-kb message
which makes the RAZ protein (an inhibitor of Z activity [21])
is also derived from Rp (35).
Given the importance of the various EBV genes transcribed
from Rp, understanding the transcriptional regulation of Rp
may yield insight into the cellular mechanisms involved in the
disruption of viral latency. Since high expression of the Z gene
product is sufficient to disrupt viral latency, activation of Z
expression through Rp could potentially lead to lytic infection.
In addition, activation of Rp is required for the production of
R and/or RAZ.
Currently, very little is known regarding the cellular and viral
regulation of Rp. Both Zp and Rp are normally inactive in
latently infected cells (2, 18, 33, 51). Agents which disrupt viral
latency (such as TPA and antiimmunoglubulin antibody) also
activate expression of Zp and Rp (2, 15, 18, 19, 33, 51), and it
is presumed that disruption of viral latency proceeds through
activation of these promoters (18, 19, 22, 49). TPA- and anti-
immunoglobulin antibody-responsive elements have been
mapped in Zp (15, 19, 48), but it is currently not understood
how Rp is activated during disruption of viral latency. Al-
though we have previously shown that the cellular transcription
factor Sp1 is required for constitutive activity of Rp (55), this
factor is unlikely to mediate activation of Rp during disruption
of latency since Sp1 is ubiquitously expressed (12).
We have studied the regulation of Rp by the cellular tran-
scription factor Zif268 (also known as EGR-1, Krox 24, and
NGFI-A) (9, 34, 37, 50). Transcription of the Zif268 IE gene in
B cells is induced by TPA and antiimmunoglobulin antibody
(46, 47). The Zif268 gene product is a zinc finger protein which
binds to GC-rich regions (10). Here, we show that Zif268
activates Rp but not Zp and that TPA activation of Rp requires
a Zif268 binding site. Our data suggest that activation of Rp by
Zif268 in latently infected cells may be a mechanism for in-
ducing lytic EBV infection. The regulation of Zif268 expres-
sion in B cells may therefore play a critical role in the main-
tenance of viral latency.
MATERIALS AND METHODS
Cell lines. The D98/HE-R-1 cell line was formed by fusion of a HeLa cell
subclone (D98) with the EBV-positive Burkitt’s lymphoma cell line P3HR1 (39).
The C-33 cell line is a human cervical carcinoma line (papillomavirus negative).
B95-8 is an EBV-positive marmoset B-cell line. Schneider line 2 (SL2) is a
Drosophila embryo cell line (45). NIH 3T3 is a murine fibroblast line. All lym-
phoid cell lines were maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum. All epithelial cell lines were maintained in Dulbecco modified
Eagle medium H supplemented with 10% fetal calf serum. SL2 was maintained
in Drosophila Schneider medium (obtained from GIBCO-BRL) supplemented
with 10% fetal calf serum.
EBV plasmids. Plasmid RpBSCAT has been previously described (54) and
contains the Rp sequences (from 2962 to 15 relative to the mRNA start site)
linked to the heterologous reporter gene, chloramphenicol acetyltransferase
(CAT), in the pBS phagemid vector (Stratagene). A series of 59 deletion mutants
of Rp were also constructed as previously described (55) (the nomenclature of
the above plasmids in regard to the Rp mRNA start site has been corrected
slightly from our previous publication). Site-directed mutants of the RpBSCAT
construct were made with the Bio-RadMutaGene phagemid in vitro mutagenesis
kit according to the manufacturer’s instructions. Synthetic oligonucleotides com-
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plementary to the region to be altered introduced a new restriction site to
facilitate screening for mutants.
The Z-CAT plasmid has been previously described (30) and contains Zp
(2552 to 112 relative to the mRNA start site) sequences linked to CAT. The
EA-CAT plasmid (pEA-BS-CAT) has also been previously described and con-
tains the early BMRF1 promoter sequences (2333 to 11) linked to CAT (28).
The CMV-Z plasmid has the Z cDNA under the control of the cytomegalo-
virus promoter in the pHD1013 vector as previously described (41). The pcDZ15
plasmid contains the bicistronic 2.9-kb cDNA (derived from Rp) driven by the
simian virus 40 promoter in the pcDV vector as previously described (35). This
construct was a gift from Alain Sergeant.
Zif268 plasmids. The pCMVEgr-1 plasmid contains the mouse Zif268 cDNA
under the control of the cytomegalovirus promoter in the pCMV5 vector as
previously described (26). The Egr-1(D331-374) control vector is identical to
pCMVEgr-1 except that it is lacking some of the Zif268 zinc fingers. Both Zif268
expression vectors were gifts from Vikas Sukhatme. The pD56 EBS-13 vector (a
gift from Vikas Sukhatme) contains three copies of the consensus Zif268 site
upstream of a minimal fos promoter driving CAT. Bacterial Zif268 expression
was achieved with a vector containing the murine Zif268 cDNA inserted under
the control of the T7 promoter in plasmid Pet8C (a gift from Barbara Christy)
(10).
Sp1 plasmids. Plasmids pPacSp1 (a gift from Robert Tjian) and pPacSp1FX
have been described previously (12, 55).
DNA transfection. Plasmid DNA was purified through either Qiagen columns
as described by the manufacturer (Qiagen, Inc.) or double-banded cesium chlo-
ride gradients. Ten micrograms of DNA was transfected into cells by electropo-
ration with a Zapper electroporation unit (medical electronics shop, University
of Wisconsin) at 1,500 V. Epithelial cells were harvested and suspended into
RPMI 1640 medium prior to electroporation. NIH 3T3 and SL2 cells were
transfected by the calcium phosphate precipitation method as described previ-
ously (55).
CAT assays. Cell extracts were prepared 48 h after transfection and incubated
at 378C with [14C]chloramphenicol in the presence of acetyl coenzyme A as
described previously (24). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography followed by Phosphorimage screening or by
scintillation counting.
Production of bacterial Zif268 protein. The plasmid containing the Zif268
cDNA in the Pet8C vector was grown in Escherichia coli BL21(DE3) to an
optical density of 0.6 before addition of 0.4 mM isopropyl-b-D-thiogalactopy-
ranoside. Solubilized Zif268 protein was obtained by the procedure of Christy et
al. (10).
FIG. 1. (A) Sizes and structures of the messages originating from the Zp and
Rp. Z and R exons in genomic DNA are hatched. The positions of the two
promoters driving Z transcription (Zp and Rp) are indicated below the genomic
map. The various cDNAs derived from Zp and Rp are based upon the mapping
of Manet et al. (35). An additional cDNA (not shown) derived from Zp has the
middle exon of Z deleted (32). (B) Viral latency can be disrupted by overex-
pression of the bicistronic message making the Z and R proteins. Latently
infected D98/HE-R-1 cells were transfected with 5 mg of either vector DNA
containing the cytomegalovirus promoter, a plasmid containing the 0.9-kb Z
cDNA driven by the cytomegalovirus IE promoter, or a plasmid containing the
2.9-kb bicistronic Z15 cDNA. Whole-cell lysates of the transfected cells were
prepared 48 h after transfection, loaded onto a sodium dodecyl sulfate-polyac-
rylamide gel, and transferred to nitrocellulose. The induction of the Z and
proteins (a component of the early antigen diffuse complex) was then assessed by
immunoblotting with monoclonal antibodies specific to either the Z (lower
panel) or the BMRF1 (upper panel) protein. Although the transfected 0.9-kb Z
cDNA produced significantly more Z protein than the 2.9-kb bicistronic Z15
cDNA, transfection of either cDNA resulted in efficient induction of BMRF1
expression in D98/HE-R-1 cells.
FIG. 2. The Zif268 transcription factor activates Rp. (A) Promoter constructs (5 mg) containing either Rp (RpBSCAT), Zp (ZCAT), or the early BMRF1 promoter
(EACAT) linked to the CAT reporter gene were cotransfected into D98/HE-R-1 cells with either 5 mg of a Zif268 expression vector, CMVEgr-1 (1ZIF), or an equal
amount of a control vector, CMVEgr-1 (D331-374), containing mutant Zif268. Two days after transfection, CAT activity was measured as previously described (24).
Rp is activated by cotransfection with Zif268, whereas Zp and the BMRF1 promoter are not affected. (B) Five micrograms of either the Rp construct, RpBSCAT, or
a positive control construct containing three consensus Zif268 binding sites (EGRCAT) was cotransfected with 5 mg of either a Zif268 expression vector (1ZIF) or
the control vector into the NIH 3T3 fibroblast line. Rp, as well as the control promoter, is efficiently activated by Zif268.
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Preparation of cellular extracts. EBV-positive B95-8 cells were induced with
30-ng/ml TPA and 5 mM sodium butyrate for 5 h. Whole-cell protein extracts
were made by washing the cells twice with ice-cold phosphate-buffered saline and
then resuspending the cell pellet in a volume of 2.5 3 107 cells per ml in a buffer
consisting of 50 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
(HEPES) (pH 7.0), 250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM
dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride. Cells were lysed by
freeze-thawing twice, and the lysate was cleared by centrifugation for 10 min at
48C. The resulting supernatant was used for electromobility shift assays.
Zif268 binding assays. Electromobility shift assays were performed as previ-
ously described (23). DNA probes spanning various regions of Rp were end
labeled with 32P. Binding reactions were carried out in a buffer consisting of 20
mM HEPES (pH 7.9), 5 mM MgCl2, 0.5 mM ethylene glycol-bis(b-aminoethyl
ether)-N,N,N9,N9,-tetraacetic acid (EGTA), 50 mM KCl, 7% glycerol, 2.5 mM
phenylmethylsulfonyl fluoride, and 0.04 mM leupeptin. Poly(dI-dC) z poly(dI-
dC) (4 mg) was added as a nonspecific competitor DNA. Cellular extracts or E.
coli extracts containing the Zif268 protein were incubated in binding buffer with
nonspecific competitor DNA (with or without specific competitor DNA) at room
temperature for 15 min, and then the labelled probe (20,000 cpm) was added.
The reaction mixture was further incubated for an additional 15 min at room
temperature, loaded onto a 5% polyacrylamide gel, and run in 0.53 Tris borate
buffer at room temperature. In reactions using specific antibodies, 2 ml of poly-
clonal antibody against either Zif268, Sp1, or NF-kB (Santa Cruz Co.) was added
after the second 15-min incubation and the mixture was incubated for an addi-
tional 45 min at room temperature prior to electrophoresis.
DNase I footprinting. Binding reactions consisted of 50,000 cpm of the 59-
end-labelled probe incubated with 2 volumes of the reaction mixture used under
the electrophoretic mobility shift assay conditions described above. The reaction
mixture was incubated for 15 min at room temperature. The end-labelled probe
containing Rp sequences from 15 to 2188 was then added, and binding was
allowed to proceed for an additional 15 min at room temperature. DNase I RQ1
(Promega) was added to the reaction mixture for 60 s. After further processing,
the DNA was loaded on a 6% polyacrylamide–7 M urea gel and subjected to
electrophoresis followed by autoradiography.
Oligonucleotide probes and competitors. Labelled oligonucleotide probes in-
cluded an Rp probe (promoter sequences 2143 to 2114 relative to the RNA
start site) (AGCTTGCCTCTCTGCTGCCCACTCATACTTAAGCT and CTA
GAGCTTAAGTATGAGTGGGCAGCAGAGAGGCA) and a probe contain-
ing the CCAAT motif derived from EBV oriLyt (AGCTTGGGGGCTTCTTAT
TGGTTAATTCAGGTA and AGCTTACCTGAATTAACCAATAAGAAGC
CCCCA). The Zif268 competitor oligonucleotide contains the Zif268 binding
site (GGATCCAGCGGGGGCGAGCGGGGGCGA and CCTAGGTCGCC
CCCGCTCGCCCCCGCT) (Santa Cruz Biotechnology). The mutant Zif268
oligonucleotide contains the sequence GGATCCAGCTAGGGCGAGCTA
GGGCGA and CCTAGGTCGATCCCGCTCGATCCCGCT. The YY1 com-
petitor oligonucleotide contains the YY1 binding site from the murine leukemia
virus long terminal repeat (CTGCAGTAACGCCATTTTGCAAGGCAT and
ATGCCTTGCAAAATGGCGTTACTGCAG) (17).
Immunoblot analysis. Detection of the EBV Z and BMRF1 proteins by
immunoblot analysis was performed as previously described (56). The Z mono-
clonal antibody BZ.1 (diluted 1:50) (a gift from Alan Rickinson) was used to
detect Z expression, and the monoclonal antibody 9240 (diluted 1:40) (NEN,
Dupont) was used to detect induction of BMRF1 (EA-D). After immunoblot-
ting, proteins were visualized by the chemiluminescence method (Amersham).
RESULTS
Overexpression of the bicistronic message making the Z and
R IE proteins is sufficient to disrupt latency. It has been
previously shown that the 2.9-kb Z15 cDNA derived from Rp
can be translated into both Z and R after transfection into
COS cells (35). Northern (RNA) blot analysis from transfec-
tion experiments suggested that Z protein is derived from the
larger (bicistronic) message rather than from use of the Zp
promoter contained within the Z15 cDNA (35). In order to
assess whether overexpression of the bicistronic Z15 cDNA is
sufficient to induce the viral lytic cycle, we transfected latently
infected D98/HE-R-1 cells with either vector DNA, the
CMV-Z plasmid (containing the 0.9-kb Z cDNA), or the
pcDZ15 construct (containing the 2.9-kb Z15 cDNA). Cells
were harvested 48 h after transfection, and the samples were
processed for immunoblot analysis.
As shown in Fig. 1B, both the 0.9-kb cDNA making Z alone
and the 2.9-kb cDNA making Z and R were capable of induc-
ing expression of an early EBV protein (BMRF1) when trans-
fected into latently infected D98/HE-R-1 cells. The 0.9- and
2.9-kb cDNAs both induced early protein expression effi-
ciently, in spite of the fact that the amount of Z produced by
the bicistronic Z15 cDNA was much less than that produced by
the smaller, 0.9-kb Z cDNA. These results suggest that activa-
tion of Rp in latently infected cells could potentially lead to
disruption of latency due to the production of Z protein from
the 2.9-kb bicistronic message.
The Zif268 transcription factor activates Rp. We have pre-
viously shown that Rp is bound and regulated by the Sp1
transcription factor (55). Further analysis of the Rp sequence
suggested the possibility of one (or more) Zif268 binding sites.
To examine whether the cellular Zif268 transcription factor
can activate Rp function, we performed transient transfection
assays. As shown in Fig. 2A, the intact Rp reporter construct
(RpBSCAT) is significantly activated by cotransfection with a
Zif268 expression vector in the EBV-positive cell line D98/HE-
R-1. In contrast, a construct containing the alternative pro-
moter (Zp) for Z transcription (Z-CAT) was not activated by
cotransfection with the Zif268 vector. The early BMRF1 pro-
moter construct was also not activated significantly by Zif268.
In order to examine whether an EBV gene product is re-
quired for the activation of Rp by Zif268, we performed similar
cotransfection experiments in EBV-negative NIH 3T3 murine
fibroblasts. A control construct containing three Zif268 bind-
FIG. 3. Mapping the Zif268 responsive region in Rp. (A) A series of 59
deletions in the RpBSCAT vector (containing Rp sequences from 2962 to 15
linked to CAT in the pBS-CAT vector) was constructed as shown. (B) The ability
of Zif268 to activate the RpBSCAT and the 59 deletion plasmids was examined
in D98/HE-R-1 cells. The average fold transactivation after cotransfection with
the Zif268 expression vector versus the control vector is shown. Zif268-induced
transactivation of Rp is significantly decreased when the promoter sequences
between 2188 and 244 are deleted.
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ing sites upstream of the minimal fos promoter was activated
by Zif268 as expected (Fig. 2B). The Rp reporter construct was
also activated efficiently by cotransfection with the Zif268 ex-
pression vector in NIH 3T3 cells. These results indicate that no
EBV gene product is required for activation of Rp by Zif268.
5* deletion analysis of Rp. In order to define the region of
Rp required for activation by Zif268, we cotransfected a series
of 59 Rp deletion constructs into D98/HE-R-1 cells with the
Zif268 expression vector (Fig. 3). In this set of experiments, the
intact Rp reporter construct was activated 10-fold by cotrans-
fection with Zif268. When the Rp sequences between 2962
and 2188 were deleted, Zif268 activation was not significantly
altered. However, Zif268 activation was significantly lost when
the promoter sequences between 2188 and 244 were deleted.
These results suggest that the region between2188 and244 in
Rp contains potential sequences required for Zif268 activa-
tion.
The Zif268 protein binds directly to Rp. To determine if the
Zif268-responsive region in the Rp contains Zif268 binding
sites, electromobility shift assays were performed with an end-
labelled probe containing the Rp sequences from 2188 to 15.
As shown in Fig. 4, bacterially synthesized Zif268 protein
bound efficiently to the Rp probe. This binding was specifically
inhibited by unlabelled oligonucleotide DNA containing the
consensus Zif268 sequence but not by unlabelled oligonucleo-
tide DNA containing a YY1 binding motif. Similar results were
obtained with in vitro-translated Zif268 protein (data not
shown).
To determine the precise sites of Zif268 binding in Rp,
DNase I footprinting was performed with bacterially synthe-
sized Zif268 protein and an end-labelled Rp probe containing
the promoter sequences from 2188 to 15. As shown in Fig. 5,
two regions of protection were observed in the presence of
Zif268 protein. A very strong region of protection was mapped
to the promoter sequences between 2114 and 2143. The cen-
ter of this strong footprint contains the sequence TGCCCA
CTC, which is a seven-ninths match with the consensus Zif268
binding motif, CGCCCACGC. A weak area of protection was
also observed over the Rp sequences from 236 to 253. This
weaker footprint contains the sequence CGCCCATGC, which
is an eight-ninths match with the consensus Zif268 sequence.
Zif268 is induced in TPA-treated B95-8 cells and binds to
Rp. To determine if Zif268 protein in cellular extracts can bind
to Rp, we performed electromobility shift assays using cellular
extracts prepared from either untreated B95-8 cells (an EBV-
positive B-cell line) or B95-8 cells which had been treated with
TPA and sodium butyrate for 5 h. In the TPA-treated extracts,
a complex was observed binding to a labelled probe containing
Rp sequences between 2113 and 2141 which was specifically
sensitive to competition with unlabelled oligonucleotide com-
petitor DNA containing the Zif268 consensus binding site but
not to competition with unlabelled DNA containing a mutated
Zif268 site (Fig. 6A, lanes 5 to 7). A much smaller amount of
this complex was also present in untreated B95-8 cell extracts
(Fig. 6A, lanes 2 to 4). In contrast to the Rp probe, uninduced
and TPA-induced extracts produced identical complexes bind-
ing to a labelled control probe containing the CCAAT motif
(Fig. 6A, lanes 8 to 10).
To confirm the identity of the TPA-induced protein binding
to the Rp probe, we used polyclonal antibodies specifically
directed against Zif268, NF-kB, or Sp1. As shown in Fig. 6B,
the TPA-induced protein binding to Rp was specifically super-
shifted by polyclonal antibody directed against Zif268 but not
affected by polyclonal antibodies directed against NF-kB or
FIG. 4. Bacterially synthesized Zif268 binds to Rp. A 32P-labelled probe
containing Rp sequences (from 2188 to 15) was incubated with bacterially
synthesized Zif268 protein or bacterial extract containing the Pet8C vector alone.
Binding was assessed by an electromobility shift assay. Bacterially expressed
Zif268 binds efficiently to the Rp probe, and this binding is specifically inhibited
by unlabelled oligonucleotide competitor DNA (Zif) containing a known Zif268
binding site but not by unlabelled oligonucleotide DNA containing a YY1 bind-
ing site (YY1).
FIG. 5. Mapping of Zif268 binding sites in Rp. A 32P-end-labelled probe
containing the Rp sequences from 2188 to 15 was incubated with bacterially
synthesized Zif268 protein (Zif268) or bacterial extracts containing the Pet8C
vector alone (Pet), and the incubation was followed by treatment with DNase I.
After processing of the samples, reaction mixtures were loaded onto a 6%
sequencing gel. The regions of protection induced by Zif268 binding and the
sequence within each footprint with homology to the consensus Zif268 binding
motif (CGCCCACGC) are indicated. Lane G, G sequence ladder.
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Sp1 (Fig. 6B, lanes 5 to 7). In contrast, none of the antibodies
affected binding of proteins to another labelled probe contain-
ing the CCAAT motif (Fig. 6B, lanes 8 to 12).
Interestingly, we also observed a faster-migrating complex
binding to the Rp probe which is partially inhibited by Zif268
competitor DNA (Fig. 6A). However, since this faster-migrat-
ing complex is constitutively present in B95-8 cells, is not in-
duced by TPA, and is not recognized by Zif268 antibody, it is
clearly not Zif268. Although we have not yet precisely deter-
mined the identity of this protein, other members of the zinc
finger protein family (such as Wilms’ tumor protein [WT1] and
NGFI-C) have been previously shown to bind to Zif268 motifs
(14, 42).
Site-directed mutations of the Zif268 binding sites in Rp
reduce Zif268 activation. To examine the functional signifi-
cance of the two potential Zif268 binding sites in Rp, each
Zif268 site in the RpBSCAT vector was specifically altered by
site-directed mutation as shown in Fig. 7A. In D98/HE-R-1
cells, neither of these site-directed mutations significantly af-
fected the constitutive activity of the RpBSCAT plasmid
(data not shown). In addition, neither mutation significant-
ly decreased Sp1 responsiveness in comparison with the
wild-type promoter (Fig. 7B). However, the ability of Zif268
to activate each of these mutant constructs was significantly
decreased in comparison with the wild-type promoter. Mu-
tation of the upstream Zif268 site (which produced the
stronger footprint) reduced Zif268 responsiveness of Rp by
80% (Fig. 7C), and mutation of the weaker downstream
Zif268 binding site reduced Zif268 responsiveness by 60%.
Mutation of both sites together produced a complete inhibi-
tion of Zif268 activation. These data indicate that Zif268 ac-
tivation of Rp is mediated through two specific Zif268 binding
sites.
TPA activation of Rp requires the upstream Zif268 site.
Finally, we examined whether TPA activation of Rp is medi-
ated through Zif268 induction. C-33 cells were transfected with
either the wild-type RpBSCAT vector or the site-directed mu-
tants, and 24 h after transfection the cells were transferred to
media containing 0.5% fetal calf serum in the presence or
absence of TPA (20 ng/ml) (Fig. 7D). In this set of experi-
ments, the wild-type Rp was activated an average of eightfold
by TPA. In comparison, the mutant construct in which the
upstream Zif268 site was altered was not significantly activated
by TPA. Mutation of the downstream Zif268 site also inhibited
TPA activation, although to a lesser degree. Thus, TPA acti-
vation of Rp appears to require Zif268 binding sites.
DISCUSSION
In this report, we have demonstrated that the cellular pro-
tein Zif268 can activate expression of one of the two promoter
elements directing Z transcription. The regulation of Z is of
critical importance in the biology of the EBV, because over-
expression of the Z gene product leads to disruption of viral
latency and consequent death of the host cell. Therefore, the
cellular factors which activate (or repress) the transcription of
Z must play a key role in the regulation of EBV latency.
The Z IE gene product is a member of the bZip (leucine
zipper) family and functions as a transcriptional activator (5,
16). The Z protein has been shown to regulate early EBV
promoters by binding directly to upstream elements and acti-
vating transcription (13, 28, 29, 30, 41). Although Z can also
activate its own proximal promoter, Zp, through a direct bind-
ing mechanism (20, 53), it is not transcribed in latently infected
cells. Therefore, disruption of viral latency must initially be
mediated by a cellular factor(s) which activates Z transcription.
FIG. 6. Zif268 is induced in TPA-treated B95-8 cells and binds to Rp. (A) A 32P-labelled oligonucleotide probe spanning the Rp sequences from 2143 to 2114
was incubated with whole-cell extracts derived from either untreated B95-8 cells or B95-8 cells treated with TPA-sodium butyrate for 5 h. Binding was analyzed by
electromobility shift assay. TPA-treated extracts (lanes 5 to 7) contain increased amounts of a complex binding to the Rp probe which is specifically sensitive to
competition with unlabelled oligonucleotide competitor DNA containing the Zif268 binding motif (Zif) but not to competition with a mutant Zif268 motif (DZif). In
contrast, the untreated and TPA-treated extracts produced identical binding complexes with a labelled oligonucleotide probe containing the CCAAT motif (lanes 8 to
10). (B) Protein extract from TPA-treated B95-8 cells was incubated in binding buffer at room temperature for 15 min with various competitor oligonucleotides as
indicated; then, a labelled oligonucleotide probe (20,000 cpm) containing Rp sequences from 2143 to 2114 was added. The reaction mixture was further incubated
for an additional 15 min at room temperature. For lanes 5 to 7, 2 ml of polyclonal antibody against either Zif268, Sp1, or NF-kB was then added and the mixtures were
incubated for an additional 45 min at room temperature prior to electrophoresis. The Zif268 specific antibody (but not the other antibodies) specifically supershifted
the TPA-induced complex binding to the Rp probe. In contrast, none of the antibodies affected binding of complexes to a labelled oligonucleotide probe containing
the CCAAT motif (lanes 8 to 12).
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Subsequently, autoregulation of Z transcription by the Z trans-
activator function presumably leads to irreversible activation of
the lytic viral cascade.
Very little work has been previously published regarding the
cellular regulation of Rp. We have previously shown that Rp
(but not Zp) is responsive to the Sp1 transcription factor (55).
Sp1 activation of Rp is mediated through a series of upstream
Sp1 binding sites. The most proximal Sp1 site (located between
245 and250) overlaps the proximal Zif268 site and appears to
be critical for both Sp1 activation in Drosophila Schneider cells
and constitutive activity of Rp in epithelial cells. However,
since Sp1 is a ubiquitous housekeeping protein, the activation
of Rp function during the disruption of viral latency is unlikely
to be mediated through the Sp1 transcription factor.
In this report we have demonstrated that the cellular Zif268
protein can activate transcription of Rp. Zif268 is an IE gene
which is induced by growth factors and a variety of cell surface
stimuli (4). Both TPA and antiimmunoglobulin antibody treat-
ment can activate Zif268 transcription in B cells (46, 47). In-
terestingly, these factors are also used to disrupt EBV latency,
making this transcription factor an attractive candidate for
playing a role in EBV regulation. Our results suggest that
TPA-induced activation of Rp does indeed appear to be me-
diated through Zif268.
Zif268 is a member of a gene family that includes the IE
genes NGFI-C and Krox 20, as well as the Wilms’ tumor gene,
WT-1 (6, 14, 42). Zif268 is a phosphorylated nuclear protein
(54). The Zif268 DNA binding domain is composed of three
zinc fingers of the C2H2 subtype and binds to a GC-rich motif,
CGCCCACGC (9). Although the consensus Zif268 binding
motif is not present in Rp, we have identified two closely
related Zif268 binding sites in Rp and demonstrated that these
binding sites are required for Zif268 activation. Other genes
previously shown to be regulated by Zif268 include the Zif268
gene itself (10), adenosine deaminase (1), and a-myosin heavy
chain (26).
It has sometimes been presumed that disruption of EBV
latency is initially mediated through activation of Zp, followed
by activation of Rp (19, 22, 49). However, to our knowledge,
induction of the 0.9-kb message (derived from Zp) and that of
the 2.9- and 3.8-kb messages (derived from Rp) have always
been observed simultaneously (18, 36, 49, 51). Therefore, dis-
FIG. 7. The Zif268 sites in Rp are required for Zif268 activation. (A) Site-directed mutations of the RpBSCAT vector were constructed as shown. The sequences
of the Zif268 binding sites in Rp (shown next to the consensus Zif268 binding motif) are indicated. The site-directed mutations disrupt each of the two Zif268 binding
sites in Rp (either alone or in combination) as shown. Mutant designations reflect the Rp sequences (relative to the start site) affected. (B) Ten micrograms of the
RpBSCAT plasmid with or without a site-directed mutation altering either the proximal or the distal Zif268 binding site was transfected into Drosophila SL2 cells with
1 mg of either an Sp1 expression vector (pPacSp1) or a control vector (pPacSp1FX). Two days after transfection, CAT activity was measured as previously described
(24). Mutation of the Zif268 binding sites in the RpBSCAT plasmid does not significantly affect Sp1 activation. (C) Five micrograms of the RpBSCAT construct without
or with a site-directed mutation altering either the upstream Zif268 binding site (D125-131), the proximal Zif268 binding site (D42-44), or both sites together
(D42-44/125-131) was transfected into D98/HE-R-1 cells with 5 mg of either the Zif268 expression plasmid or a negative control vector. CAT activity was determined
2 days after transfection. The relative activity induced by Zif268 versus the negative control vector is shown. Mutation of either Zif268 site alone in Rp significantly
reduced activation by Zif268; mutation of both sites simultaneously completely inhibited Zif268 activation. (D) Five micrograms of the RpBSCAT construct without
or with a site-directed mutation altering either the upstream Zif268 binding site (D125-131), the proximal Zif268 binding site (D42-44), or both sites together
(D42-44/125-131) was transfected into C-33 cells. Twenty-four hours after transfection, the cells were transferred to media containing 0.5% fetal calf serum (0.5%) in
the presence (20 ng/ml) or absence of TPA. CAT activity was determined after an additional 24 h (after correction for protein concentration). The relative activation
induced by TPA in comparison with the wild-type promoter is shown (the wild-type RpBSCAT plasmid was activated an average of eightfold by TPA treatment in this
set of experiments). Mutation of the upstream Zif268 site in Rp significantly reduced activation by TPA.
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ruption of viral latency could potentially be mediated through
activation of Rp, since the bicistronic messages derived from
this promoter could potentially make a small amount of Z
protein, which then leads to activation of Zp. We have dem-
onstrated in this report that overexpression of the Rp-derived
2.9-kb message in latently infected cells does result in detect-
able production of Z protein and is sufficient to disrupt viral
latency. The hypothesis that Rp activation may actually pre-
cede Zp activation is also supported by previous findings from
our laboratory which suggest that Zp, but not Rp, is activated
by Z (55). However, our findings are in contrast to those of
another group (49), which found that Z induces low-level ac-
tivation of Rp in cotransfection assays.
Alternatively, it is quite possible that disruption of latency
requires the simultaneous activation of both Zp and Rp. In this
case, activation of Rp could be required primarily for expres-
sion of R rather than the production of Z. The EBV IE gene
product, R, is a transcriptional activator which activates ex-
pression of early EBV promoters containing upstream R bind-
ing sites (3, 13, 25, 27–29, 41). It has been reported by several
groups that the combination of Z and R is required for max-
imal activation of a variety of early EBV promoters in transient
transfection assays (7, 8, 13, 28, 41). Optimal disruption of
latency may, likewise, require the simultaneous expression of
both Z and R.
Rp also appears to be the major promoter regulating tran-
scription of RAZ mRNA. Therefore, activation of Rp could
potentially increase expression of RAZ (in addition to R and
Z), although the relative abundance of the 0.9-kb RAZ mes-
sage versus the 2.8-kb bicistronic R/Z message is likely to be
controlled at the level of RNA splicing. RAZ is currently
thought to function as a negative regulator of Z (21). However,
the biological function of RAZ remains relatively unexplored,
and it remains possible that RAZ expression actually plays a
role in the disruption of viral latency. For example, RAZ could
potentially mediate the transition from early to late gene ex-
pression.
There is still some controversy in regard to whether Z and R
are true IE genes (i.e., their expression is independent of
protein synthesis) (18, 33, 40). Since Zif268 is an IE gene,
rather than an IE protein, the induction of Zif268 protein by
TPA or antiimmunoglobulin antibody clearly does require pro-
tein synthesis. One study has found that induction of Z and R
transcription by TPA requires protein synthesis (33), suggest-
ing that Z and R are not true IE genes. Two other studies have
found that, although the great majority of Z/R transcription
(following antiimmunoglobulin induction) is inhibited in the
absence of protein synthesis, a very small amount still occurs
(18, 40). However, in the latter two studies, it is possible that
protein synthesis inhibition was not complete.
Although the relative importance of Rp versus Zp as a
source of Z protein remains unclear, the fact that Rp and Zp
activation occurs essentially simultaneously during disruption
of viral latency (18, 40) suggests that Rp plays an important
role in this event. Our finding that Zif268 can activate Rp
suggests that the cellular regulation of Zif268 may be one of
the factors which influences the stringency of EBV latency.
Whether Zif268 activation is the critical first step which ini-
tiates disruption of viral latency remains to be determined.
ACKNOWLEDGMENTS
We thank Joseph Pagano and Nancy Raab-Traub for critical reading
of the manuscript. We thank Vikas Sukhatme for the Zif268 expres-
sion vectors and reporter construct and Barbara Christy for the Zif268
bacterial expression vector. We thank Alain Sergeant for the Z and
Z15 cDNA vectors and Alan Rickinson for the Z monoclonal antibody.
We thank Judy Hall for preparation of the manuscript.
This work was supported by grants R01 CA58853 and K04-CA01711
from the National Institutes of Health.
REFERENCES
1. Ackerman, S., A. Minden, G. Williams, C. Bobonis, and C. Yeung. 1991.
Functional significance of an overlapping consensus binding motif for Sp1
and zif268 in the murine adenosine deaminase gene promoter. Proc. Natl.
Acad. Sci. USA 88:7523–7527.
2. Biggen, M., M. Bodescot, M. Perricaudet, and P. Farrell. 1987. Epstein-Barr
virus gene expression in P3HR1-superinfected Raji cells. J. Virol. 61:3120–
3132.
3. Buisson, M., E. Manet, M. C. Trescol-Biemont, H. Gruffat, B. Durand, and
A. Sergeant. 1989. The Epstein-Barr virus early protein EB2 is a post-
transcriptional activator expressed under control of EBV transcription fac-
tors EB1 and R. J. Virol. 63:5276–5284.
4. Cao, X., R. A. Koski, A. Gashler, M. McKiernan, C. F. Morris, R. Gaffney,
R. V. Hay, and V. P. Sukhatme. 1990. Identification and characterization of
the Egr-1 gene product, a DNA-binding zinc finger protein induced by
differentiation and growth signals. Mol. Cell. Biol. 10:1931–1939.
5. Chang, Y., D. Dong, G. Hayward, and S. D. Hayward. 1990. The Epstein-
Barr virus Zta transactivator: a member of the bZIP family with unique
DNA-binding specificity and a dimerization domain that lacks the charac-
teristic heptad leucine zipper motif. J. Virol. 64:3358–3369.
6. Chavier, P., C. Vesque, B. Galliot, M. Vigneron, P. Dolle, D. Duboule, and P.
Charnay. 1990. The segment specific gene krox 20 encodes a transcription
factor with binding sites in the promoter region of the Hox 1.4 gene. EMBO
J. 9:1209–1218.
7. Chevallier-Greco, A., H. Gruffat, E. Manet, A. Calender, and A. Sergeant.
1989. The Epstein-Barr virus (EBV) DR enhancer contains two functionally
different domains: domain A is constitutive and cell specific, domain B is
transactivated by the EBV early protein R. J. Virol. 63:615–623.
8. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A.
Sergeant. 1986. Both Epstein-Barr virus (EBV) encoded trans-acting factors,
EB1 and EB2, are required to activate transcription from an early EBV
promoter. EMBO J. 5:3243–3249.
9. Christy, B., and D. Nathans. 1988. A gene activated in mouse 3T3 cells by
serum growth factors encodes a protein with ‘‘zinc finger’’ sequences. Proc.
Natl. Acad. Sci. USA 85:7857–7861.
10. Christy, B., and D. Nathans. 1989. DNA binding site of the growth-inducible
protein zif268. Proc. Natl. Acad. Sci. USA 86:8737–8741.
11. Countryman, J., and G. Miller. 1985. Activation of expression of latent
Epstein-Barr virus after gene transfer with a small cloned fragment of het-
erogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085–4089.
12. Courey, A., and R. Tjian. 1988. Analysis of Sp1 in vivo reveals multiple
transcriptional domains, including a novel glutamine-rich activation motif.
Cell 55:887–898.
13. Cox, M., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the
divergent promoter of Epstein-Barr virus responds synergistically to the R
and Z transactivators. J. Virol. 64:313–321.
14. Crosby, S. D., J. J. Puetz, K. S. Simburger, T. J. Fahrner, and J. Milbrandt.
1991. The early response gene NGFI-C encodes a zinc finger transcriptional
activator and is a member of the GCGGGGGCG (GSG) element-binding
protein family. Mol. Cell. Biol. 11:3835–3841.
15. Daibata, M., S. Speck, C. Mulder, and T. Sairenji. 1994. Regulation of the
BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immu-
noglobulin-treated B cells. Virology 198:446–454.
16. Farrell, P., D. Rowe, C. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus
BZLF1 trans-activator specifically binds to consensus Ap1 site and is related
to c-fos. EMBO J. 8:127–132.
17. Flanagan, J., K. Becker, D. Ennist, S. Gleason, P. Driggers, B. Levi, E.
Appela, and K. Ozato. 1992. Cloning of a negative transcription factor that
binds to the upstream conserved region of Moloney murine leukemia virus.
Mol. Cell. Biol. 12:38–42.
18. Flemington, E. K., A. E. Goldfield, and S. H. Speck. 1991. Efficient tran-
scription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1
genes requires protein synthesis. J. Virol. 65:7073–7077.
19. Flemington, E., and S. H. Speck. 1990. Identification of phorbol ester re-
sponse elements in the promoter of Epstein-Barr virus putative lytic switch
gene BZLF1. J. Virol. 64:1217–1226.
20. Flemington, E., and S. H. Speck. 1990. Autoregulation of Epstein-Barr virus
putative lytic switch gene BZLF1. J. Virol. 64:1227–1232.
21. Furnari, F., V. Zacny, E. B. Quinlivan, S. Kenney, and J. Pagano. 1994.
RAZ, an Epstein-Barr virus transdominant repressor that modulates the
viral reactivation mechanism. J. Virol. 68:1827–1836.
22. Garcia-Blanco, M., and B. Cullen. 1991. Molecular basis of latency in patho-
genic human viruses. Science 254:815–820.
23. Garner, M., and A. Revzin. 1981. A gel electrophoresis method for quanti-
fying the binding of proteins to specific DNA regions: application to com-
ponents of the Escherichia coli lactose operon regulatory system. Nucleic
Acids Res. 9:3047–3060.
3822 ZALANI ET AL. J. VIROL.
24. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant ge-
nomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol. 2:1044–1051.
25. Gruffat, H., N. Duran, M. Buisson, F. Wild, R. Buckland, and A. Sergeant.
1992. Characterization of an R-binding site mediating the R-induced trans-
activation of the Epstein-Barr virus BMLF1 promoter. J. Virol. 66:46–52.
26. Gupta, M., M. Gupta, R. Zak, and V. Sukhatme. 1991. Egr-1, a serum
inducible zinc finger protein, regulates transcription of the rat cardiac a-my-
osin heavy chain gene. J. Biol. Chem. 266:12813–12816.
27. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-
Barr virus transactivator, R, induces expression of a cytoplasmic early anti-
gen. J. Virol. 62:2274–2284.
28. Holley-Guthrie, E. A., E. B. Quinlivan, E.-C. Mar, and S. Kenney. 1990. The
Epstein-Barr virus (EBV) promoter for early antigen (EA-D) is regulated by
the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J.
Virol. 64:3753–3759.
29. Kenney, S., E. Holley-Guthrie, E.-C. Mar, and M. Smith. 1989. The Epstein-
Barr virus BMLF1 promoter contains an enhancer element that is responsive
to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878–3883.
30. Kenney, S., J. Kamine, E. Holley-Guthrie, J.-C. Lin, E.-C. Mar, and J.
Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene
product differentially affects latent versus productive EBV promoters. J.
Virol. 63:1729–1736.
31. Kieff, E., and D. Leibowitz, 1990. Epstein-Barr virus and its replication, p.
1889–1920. In B. Fields, D. Knipe, et al. (ed.), Virology, 2nd ed. Raven Press,
New York.
32. Lau, R., G. Packham, and P. Farrell. 1992. Differential splicing of Epstein-
Barr virus immediate-early RNA. J. Virol. 66:6233–6236.
33. Laux, G., U. K. Freese, R. Fischer, A. Polack, E. Kofler, and G. Bornkamm.
1988. TPA-inducible Epstein-Barr virus genes in Raji cells and their regu-
lation. Virology 162:503–507.
34. Lemaire, P., O. Revelant, R. Bravo, and P. Charnay. 1988. Two mouse genes
encoding potential transcription factors with identical DNA-binding do-
mains are activated by growth factors in cultured cells. Proc. Natl. Acad. Sci.
USA 85:4691–4695.
35. Manet, E., H. Gruffat, M. C. Trescol-Biemont, I. Moreno, P. Chambard, J. F.
Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNA’s gener-
ated by facultative splicing code for two transcriptional trans-activators.
EMBO J. 8:1819–1826.
36. Mellinghoff, I., M. Daibata, R. Humphreys, C. Mulder, K. Takada, and T.
Sairenji. 1991. Early events in Epstein-Barr virus genome expression after
activation: regulation by second messengers of B cell activation. Virology
185:922–928.
37. Milbrandt, J. 1987. A nerve growth factor-induced gene encodes a possible
transcriptional regulatory factor. Science 238:797–799.
38. Miller, G. 1990. The Epstein-Barr virus, p. 1921–1957. In B. Fields, D. Knipe,
et al. (ed.), Virology, 2nd ed. Raven Press, New York.
39. Moar, M., R. Ber, G. Klein, A. Westman, and I. Eriksson. 1978. Somatic cell
hybrids between human lymphoma cell lines. V. IdUrd inducibility and
P3HR-1 superinfectability of DAUDI/HeLa (DAD) and DAUDI/P3HR-1
(DIP-1) cell lines. Int. J. Cancer 22:669–674.
40. Packham, G., M. Brimmell, D. Cook, A. Sinclair, and P. Farrell. 1993. Strain
variation in Epstein-Barr virus immediate-early genes. Virology 192:541–550.
41. Quinlivan, E., E. Holley-Guthrie, M. Norris, D. Gutsch, S. Bachenheimer,
and S. Kenney. 1993. Direct BRLF1 binding is required for cooperative
BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter,
BMRF1. Nucleic Acids Res. 21:1999–2007.
42. Rauscher, F., J. Morris, O. Tournay, D. Cook, and T. Curran. 1990. Binding
of the Wilms’ tumor locus zinc finger protein to the EGR-1 consensus
sequence. Science 250:1259–1262.
43. Rooney, C., D. Rowe, T. Ragot, and P. Farrell. 1989. The spliced BZLF1 gene
of Epstein-Barr virus transactivates an early EBV promoter and induces the
virus productive cycle. J. Virol. 63:3109–3116.
44. Rooney, C., N. Taylor, J. Countryman, H. Jenson, J. Kolman, and G. Miller.
1988. Genome rearrangements activate the Epstein-Barr virus gene whose
product disrupts latency. Proc. Natl. Acad. Sci. USA 85:9801–9805.
45. Schneider, I. 1972. Cell lines derived from late embryonic stages of Dro-
sophila melanogaster. J. Embryol. Exp. Morphol. 27:353–365.
46. Seyfert, V., S. McMahon, W. Glenn, A. Yellen, V. Sukhatme, X. Cao, and J.
Monroe. 1990. Methylation of an immediate-early inducible gene as a mech-
anism for B cell tolerance induction. Science 250:797–800.
47. Seyfert, V. L., V. P. Sukhatme, and J. G. Monroe. 1989. Differential expres-
sion of a zinc finger-encoding gene in response to positive versus negative
signaling through receptor immunoglobulin in murine B lymphocytes. Mol.
Cell. Biol. 9:2083–2088.
48. Shimuzu, N., and K. Takada. 1993. Analysis of the BZLF1 promoter of the
Epstein-Barr virus: identification of an anti-immunoglobulin response se-
quence. J. Virol. 67:3240–3245.
49. Sinclair, A., M. Brimmel, F. Shanahan, and P. Farrell. 1991. Pathways of
activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237–2244.
50. Sukhatme, V. P., X. Cao, L. C. Chang, C. H. Tsai-Morris, D. Stamenkovich,
P. C. Ferreira, D. R. Cohen, S. A. Edwards, T. B. Shows, T. Curran, M. M.
Le Beau, and E. D. Adamson. 1988. A zinc-finger encoding gene coregulated
with c-fos during growth and differentiation, and after cellular depolariza-
tion. Cell 53:37–43.
51. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of
latently infected Epstein-Barr virus genomes. J. Virol. 63:445–449.
52. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the
latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA
fragment. J. Virol. 57:1016–1022.
53. Urier, G., M. Buisson, P. Chambar, and A. Sergeant. 1989. The Epstein-Barr
virus early protein EB1 activates transcription from different responsive
elements including Ap1 binding sites. EMBO J. 8:1447–1453.
54. Waters, C. M., D. C. Hancock, and G. I. Evans. 1990. Identification and
characterization of the egr-1 gene product as an inducible, short-lived, nu-
clear phosphoprotein. Oncogene 5:669–674.
55. Zalani, S., E. Holley-Guthrie, D. Gutsch, and S. Kenney. 1992. The Epstein-
Barr virus (EBV) immediate-early promoter, BRLF1, can be activated by the
cellular Sp1 transcription factor. J. Virol. 66:7282–7292.
56. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical inter-
action between p53 and BZLF1: implications for Epstein-Barr virus latency.
Mol. Cell. Biol. 14:1929–1938.
57. Zur Hausen, H., G. Bornkamm, R. Schmidt, and E. Hecker. 1979. Tumor
initiators and promoters in the induction of Epstein-Barr virus. Proc. Natl.
Acad. Sci. USA 76:782–785.
VOL. 69, 1995 Zif268 ACTIVATES THE BRLF1 PROMOTER 3823
